Acepromazine

Exact current Georgian and Italian/EU authorisations, a full-application basis, detailed SPC and FDA-approved same-strength oral dog-tablet control make identity and the dog endpoint highly verifiable. They do not supply Killitam bioequivalence or validate every legacy claim.

Acepromazine can produce oral/OTM sedation, but response is variable: an oral randomized study found only slight ataxia in 2/8 acepromazine-only dogs, while a small OTM trial showed sedation with lower pressure. Exact-product outcomes and support for the broad legacy claims are absent.

The 0.5-3 mg/kg label reaches far above contemporary low-dose protocols. Hypotension/collapse, hypothermia, altered haematology, prolonged or paradoxical CNS effects and absent specific reversal materially narrow use; patient, breed and ABCB1 sensitivity remain important.

Oral use avoids injection and label onset is 40-60 minutes, but the smallest supported half is 5 mg, already 0.5 mg/kg in a 10 kg dog. The tablet is not described as scored and neither smaller fractions nor crushing are validated; response observation and recovery planning are prolonged.

Exact current Georgian and Italian/EU dog/cat authorisations and detailed SPC make identity highly verifiable. However, no exact-product public feline outcome dossier or current internationally authorised feline oral comparator was found.

Acepromazine is pharmacologically active in cats, but current evidence describes variable response and only mild combination sedation at 0.05 mg/kg. This is parenteral evidence; direct oral Killitam feline outcomes and evidence for the broad legacy claims are absent.

The 1.5-4.5 mg/kg oral label is extremely high relative to modern 0.01-0.05 mg/kg parenteral guidance; hypotension occurred even at 0.05 mg/kg with opioids and worsened after propofol. No specific reversal and variable feline response leave a narrow safety margin.

Oral use avoids injection and label onset is 20-40 minutes, but the smallest supported 5 mg half is about 1.43 mg/kg in a 3.5 kg cat and cannot deliver contemporary low-dose protocols. Unvalidated smaller fractions, variable effect and monitored recovery substantially reduce practicality.

The exact product has current Georgian and Italian/EU prescription authorisations, a full-application legal basis and a detailed current SPC. Its 1983 origin, absent public exact-product outcome dossier and major dose divergence from current guidance and the GB comparator limit confidence.

Acepromazine reliably sedates many healthy dogs and reduces anaesthetic requirements, including in a randomized trial at 0.05 mg/kg. Response is variable, it does not provide adequate analgesia, and the exact 0.25-1 mg/kg label range is far above modern low-dose protocols, so depth and benefit are less predictable.

Dose-dependent hypotension, hypothermia, collapse, dysrhythmia, prolonged depression and paradoxical excitation/seizures are important and there is no specific antagonist. Label doses magnify concern; hypovolaemia, cardiac/hepatic disease, epilepsy, brachycephaly, large breeds and ABCB1 risk materially narrow safe use.

A single clinic injection, slow-IV option and 15-30-minute premedication timing are workable. However, 10 mg/ml is poorly suited to precise contemporary low dosing, full monitoring and recovery observation are necessary, and anaesthetic/analgesic doses must be coordinated rather than administered independently.

The exact product has current Georgian and Italian/EU prescription authorisations, a full-application legal basis and a detailed current SPC. Its 1983 origin, absent public exact-product outcome dossier and major dose divergence from current feline guidance and the GB comparator limit confidence.

Feline response is specifically described as inconsistent in current guidance. A randomized trial using 0.05 mg/kg with an opioid produced only mild sedation, while the exact label recommends 0.5-2 mg/kg; that 10-40-fold gap and absent Prequillan outcome trials make the labelled depth hard to predict.

The label range is 10-200 times the AAFP 0.01-0.05 mg/kg range depending on indication and endpoint. Hypotension occurred even at 0.05 mg/kg in an opioid-combination cat trial and worsened after propofol; no specific antagonist, hypothermia, prolonged depression and paradoxical reactions further narrow the margin.

A single clinic injection is simple in principle, but a fractious cat, slow-IV access and monitoring can be difficult. The 10 mg/ml concentration makes guideline-sized feline volumes impractically small without a validated dilution/precision plan, while prolonged observation and coordinated anaesthetic reduction remain necessary.

The exact product has a detailed current AEMPS SPC, a current multi-country EU/EEA authorisation record and current Georgian registration. Composition, dog indications, PK, dose tables, both syringe designs and extensive safety limits are transparent; independent exact-Sedan outcome and pharmacovigilance data remain limited.

Acepromazine is an established canine tranquiliser and premedicant; the exact label includes oral PK and a small randomised study supports clinically relevant oral sedation near 2 mg/kg. Evidence for this exact gel and 1–3 mg/kg spectrum is mostly regulatory, response varies materially, and it supplies negligible analgesia or reliable control of severe fear/aggression.

Correctly selected healthy dogs often tolerate acepromazine, but alpha-1 blockade can cause prolonged hypotension, tachycardia/arrhythmia, hypothermia, ataxia and non-reversible excessive sedation; paradoxical excitation/aggression is possible. ABCB1, small-device precision, major comorbidity exclusions and clinically important interactions narrow the safe population.

Oral gel avoids injection and has predictable labelled onset, but it must reach the tongue root and be swallowed, is not reversible, and can last about four hours. The Georgian 10 ml syringe moves only in 0.5 ml steps, making dogs under 17.5 kg and reduced ABCB1 doses difficult to deliver accurately; monitoring and a quiet setting remain necessary.